• Dr. C. W. Tornøe (Novo Nordisk, Måløv, Denmark)

    Dr. C. W. Tornøe (Novo Nordisk, Måløv, Denmark)

      zoom

Protein Synthesis and Crystallization of Bowman–Birk Protease Inhibitors

Christian Tornøe reports the protein synthesis and crystallization of Bowman–Birk protease inhibitors.

Divergent Protein Synthesis of Bowman–Birk Protease Inhibitors, their Hydrodynamic Behavior and Co-crystallization with α-Chymotrypsin: C. W. Tornøe, E Johansson, P.-O. Wahlund
Synlett 2017, 28, DOI: 10.1055/s-0036-1588840

Protein–protein interactions (PPIs) regulate a number of essential biochemical processes as well as cellular events. Modulation of PPIs is emerging as an attractive strategy in drug discovery. The group of Dr. Christian W. Tornøe at Novo Nordisk (Måløv, Denmark) has recently published the synthesis of analogues of small (71 amino acids) highly compact and stable proteins, their capacity to inhibit α-chymotrypsin and their co-crystallization with the latter, which allowed a detailed study of the PPIs involved in the molecular recognition process.

  • Christian Tornøe reports the protein synthesis and crystallization of Bowman–Birk protease inhibitors.

    Protein synthesis and crystallization of Bowman–Birk protease inhibitors

      zoom

Dr. Tornøe said: “In this paper, we use a divergent protein synthesis approach to modulate PPIs with disulfide-rich proteins, Bowman–Birk protease inhibitor analogues, demonstrating that native chemical ligation can be used to access complex molecular diversity in an efficient manner.” 

Get Trial Access to the chemistry journals
Download SYNFORM or read it online